Prevention and Treatment of SARS-CoV2 Infection in People Living with HIV: The Need for Specific Data

5Citations
Citations of this article
27Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The HIV pandemic has led to close to 40 million people living with HIV (PLWH) worldwide. To date, SARS-CoV2 has affected > 220 million people, and unprecedented global efforts have resulted in almost 6000 million doses of SARS-CoV2 vaccines being administered. Although several specific COVID-19 antiviral and anti-inflammatory treatments and SARS-CoV2 vaccines have been approved, the data available to support their use in specific populations such as PLWH remain limited. PLWH includes a range of individuals from practically unaffected immunity to severely immunocompromised individuals, and preventive and therapeutic interventions should be tailored for these subgroups. However, in most randomized clinical trials regarding antivirals, immunomodulators and vaccines for COVID-19, PLWH have been excluded or only enrolled in small numbers leading to a paucity of data. We briefly discuss the current evidence for prevention and treatment of COVID-19 in PLWH and identify key areas where more information is required.

Cite

CITATION STYLE

APA

Díaz, N. A., de Miguel, R., Agüero, F., Sued, O., Arribas, J. R., Ambrosioni, J., … Muñoz, J. (2022, February 1). Prevention and Treatment of SARS-CoV2 Infection in People Living with HIV: The Need for Specific Data. Infectious Diseases and Therapy. Adis. https://doi.org/10.1007/s40121-021-00547-y

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free